Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
McKinsey
Mallinckrodt
Moodys
Express Scripts

Last Updated: October 24, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208400

See Plans and Pricing

« Back to Dashboard

NDA 208400 describes XATMEP, which is a drug marketed by Silvergate Pharms and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the XATMEP profile page.

The generic ingredient in XATMEP is methotrexate sodium. There are twenty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the methotrexate sodium profile page.
Summary for 208400
Tradename:XATMEP
Applicant:Silvergate Pharms
Ingredient:methotrexate sodium
Patents:3
Formulation / Manufacturing:see details
Pharmacology for NDA: 208400
Suppliers and Packaging for NDA: 208400
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
XATMEP methotrexate sodium SOLUTION;ORAL 208400 NDA Silvergate Pharmaceuticals, Inc. 52652-2001 52652-2001-1 120 mL in 1 BOTTLE (52652-2001-1)
XATMEP methotrexate sodium SOLUTION;ORAL 208400 NDA Silvergate Pharmaceuticals, Inc. 52652-2001 52652-2001-6 60 mL in 1 BOTTLE (52652-2001-6)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrengthEQ 2MG BASE/ML
Approval Date:Apr 25, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Apr 25, 2024
Regulatory Exclusivity Use:TREATMENT OF OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PERSISTENT OLIGOARTHRITIS, PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR UNDIFFERENTIATED ARTHRITIS) & POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN 0-16 YRS
Regulatory Exclusivity Expiration:Apr 25, 2024
Regulatory Exclusivity Use:TREATMENT OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS A COMPONENT OF A COMBINATION CHEOMOTHERAPY MAINTENANCE REGIMEN
Patent:  Start TrialPatent Expiration:Jan 2, 2033Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Dow
Express Scripts
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.